Dale Mohar is a Rheumatology/Immunology physician affiliated with Kerrville VA Medical Center. OpenAlex indexes 27 publications with 249 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
708 Hill Country Dr
Ste 400
Kerrville, TX 780286071
Telephone
830-896-1433Provider last certified this registry record 31 Oct 2023.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202514 payments
- GENZYME CORPORATIONProgram year202510 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
82.3%Leukotriene Receptor Antagonist33.7%Montelukast Sodium100%Part D≥238 patientsHistamine-1 Receptor Antagonist19.1%Azelastine Hcl58%Levocetirizine Dihydrochloride39%Azelastine-Fluticasone3%Part D<11 patients+ 4 more classes in this area
Anti-infectives
8.6%Cephalosporin Antibacterial3.8%Cefuroxime80%Cefdinir20%Part D≥63 patientsMacrolide Antimicrobial1.9%Azithromycin70%Clarithromycin30%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
8.3%Corticosteroid7.6%Prednisone100%Part D≥140 patientsH2 blocker0.6%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis
Annals of Allergy Asthma & Immunology
2019 - Quality of Life Improvements Following Treatment with Olopatadine/Mometasone Combination Nasal Spray in Patients with Seasonal Allergic Rhinitis: A Pooled Analysis
Journal of Allergy and Clinical Immunology
2019 - OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY EFFECTIVELY IMPROVES SEASONAL ALLERGIC RHINITIS NASAL SYMPTOMS AND QUALITY OF LIFE
Annals of Allergy Asthma & Immunology
2018 - Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies
Allergy Asthma and Clinical Immunology
2017 - P433 Efficacy and safety of once-daily and twice-daily olopatadine/mometasone nasal spray treatment in seasonal allergic rhinitis
Annals of Allergy Asthma & Immunology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”